Loading...
•
Jun 30, 2023
Immunome Q2 2023 Earnings Report
Reported financial results for the second quarter ended June 30, 2023.
Key Takeaways
Immunome reported its financial results for the second quarter ended June 30, 2023, and provided a corporate update, highlighting the potential synergy between Morphimmune’s Targeted Effector Platform and Immunome’s Discovery Engine following the anticipated merger completion by the end of the year.
Financial results for the second quarter ended June 30, 2023, were reported.
A corporate update was provided.
The potential synergy between Morphimmune’s Targeted Effector Platform and Immunome’s Discovery Engine was highlighted.
The merger is expected to be completed by the end of the year.
Forward Guidance
The company provided forward-looking statements regarding the anticipated completion and effects of the proposed merger and private placement, planned clinical programs, the potential of the combined company’s product candidates, and the expected trading of the combined company’s stock on Nasdaq.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...